InvestSMART

Polynovo Limited (ASX:PNV)

ALERT: Price-sensitive ASX Announcement for PNV
Current share price for PNV : $0.990 -0.275 (-21.74%)+
Announcement
Release
20 Oct 2025 9:46AM
Price at Release
$1.265
Full Release
download
Summary
PolyNovo Limited reported strong unaudited trading results for the first quarter of the fiscal year 2026. The company achieved a 33.3% increase in group sales, reaching A$34.7 million compared to the same period last year. Sales in the U.S. market rose by 33.4%, while international sales grew by 33.1%. Notably, NovoSorb MTX sales experienced significant growth of 174.8%. The company also reported improvements in customer collections in the U.S. and a reduction in days sales outstanding from 95 to 61 days. PolyNovo's new R&D Innovation Centre is complete, and the new manufacturing facility is nearly operational. The quarter was EBITDA positive, and the company reported a cash balance of A$23.2 million as of 30 September 2025. The company is optimistic about entering the U.S. outpatient market and expanding the use of NovoSorb MTX globally, with significant sales growth observed in countries like Turkey, Germany, and Canada.
Key Points
  • Q1 FY26 group sales were A$34.7m, up 33.3% from A$26.0m last year.
  • U.S. sales increased by 33.4% to A$27.4m.
  • International sales grew by 33.1% to A$7.3m.
  • NovoSorb MTX sales surged by 174.8%.
  • Days sales outstanding in the U.S. improved to 61 days.
  • New R&D Innovation Centre completed.
  • New manufacturing facility requires A$2.5m to be operational.
  • Q1 FY26 was EBITDA positive with A$23.2m cash on hand.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.